Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Cancer
- Delivery
- Disease
- Antibody
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 260369
The University grants to Licensee a world-wide co-exclusive license under other certain Regents Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.
— lmmunoliposomes that Optimize Internalization into Target Cells;
— Preparation of Stable Formulations of Liposome-Plasrnid DNA Complexes for Efficient In Vivo Gene Delivery;
— Protein-Conjugated Lipidic Microparticles;
— Method for Selection of Internalizing Antibodies; and,
— Method for Selecting Cell Binding and Internalizing Ligands.
IPSCIO Record ID: 261812
The Regents and Licensee now wish to amend their Agreement to grant Licensee a sublicense to the Third Party Patent Rights and to amend certain other provisions of the Agreement in accordance with the terms of the Agreement and Amendment.
This amendment adds
— the exclusive license granted to Licensee is reduced to a non-exclusive license to the extent of the grant of rights to Third Party by The Regents to conduct Activities under the Agreement and Amendment.
— subject to the limitations set forth in this Agreement, The Regents grants to Licensee a non-exclusive license to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law under its non-exclusive license under the Third Party Patent Rights granted under the Agreement and Amendment.
The Third Party Product will mean a product developed under the Program which is composed of the Targeting Technology and the Internalizing Technology combined with a System containing doxorubicin, with or without the Micellar Conjugation Technology,
Internalizing Technology will mean Hermes proprietary cellular internalization technology solely to the extent that it relates to the internalization of a targeted liposome containing doxorubicin into a tumor cell.
Micellar Conjugation Technology will mean the standard operating procedure used by Lcensee and/or the National Cancer Institute for linking the Targeting Technology to pegyiated liposomes.
IPSCIO Record ID: 260370
The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.
— High Affinity Human Antibodies to Novel Tumor Antigens;
— Bi-specific Single Chain Fv scFv Antibody Molecule; and,
— Human Erb-B Antibodies.
